Regeneron’s sales and adjusted profit per share rose, and 3 drugs set quarterly sales records. Eylea HD faces pricing pressure, older Eylea demand is expected to fall, and biosimilar competition is growing, but gains across several drugs support a positive reading.
The gains suggest stronger demand across several important medicines and more income from the Sanofi partnership. Eylea HD still faces pricing pressure, falling demand for older Eylea, and new biosimilar rivals. Broad gains across several drugs support a positive reading.
The story reports more collaboration revenue for Regeneron, but gives no change in Sanofi’s own sales or profits. It does not change Sanofi’s outlook here.
Follow Regeneron Pharmaceuticals Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGN